{"id":60437,"date":"2024-02-28T06:48:51","date_gmt":"2024-02-28T06:48:51","guid":{"rendered":"https:\/\/medsname.com\/rioci-1\/"},"modified":"2026-05-01T10:49:16","modified_gmt":"2026-05-01T10:49:16","slug":"rioci-1","status":"publish","type":"product","link":"https:\/\/medsbase.com\/nb\/product\/rioci-1\/","title":{"rendered":"Rioci 1"},"content":{"rendered":"

<\/p>\n

\n

⚡ Quick Answer — What is Rioci 1?<\/h3>\n

Rioci 1<\/strong> is 1 mg riociguat tablets from a WHO-GMP certified manufacturer — a soluble guanylate cyclase (sGC) stimulator for pulmonal arteriell hypertensjon (PAH)<\/strong>. PAH er en spesifikk, progressiv og sjelden sykdom \u2014 ikke det samme som systemisk hypertensjon<\/strong>. It raises pressure in the pulmonary arteries, not the systemic arteries, and requires dedicated specialist-directed therapy at an accredited PAH centre. Riociguat was introduced by Bayer in 2013 as Adempas<\/strong> — the first sGC stimulator approved for human use. FDA-approved for two specific forms of pulmonary hypertension: pulmonary arterial hypertension (PAH, WHO Group 1) and chronic thromboembolic pulmonary hypertension (CTEPH, WHO Group 4) — the only oral drug approved for inoperable CTEPH. directly activates soluble guanylate cyclase (the NO receptor) in pulmonary arterial smooth muscle, raising cGMP and producing pulmonary vasodilation. Unlike PDE5 inhibitors, riociguat stimulates sGC even in the absence of NO, giving activity in NO-deficient vascular beds characteristic of PAH and CTEPH. Dosing: Start 1 mg three times daily (8-hour intervals); titrate every 2 weeks by 0.5 mg increments based on systolic BP (must remain >95 mmHg) and symptoms. Target dose 2.5 mg three times daily. PAH treatment is typically combination therapy initiated and monitored at a specialist centre; this is not a DIY disease.<\/p>\n<\/div>\n

\nHva du f\u00e5r med MedsBase:<\/strong> WHO-GMP-sertifisert produsent \u00b7 Diskret emballasje \u00b7 Verdensomspennende levering \u00b7 1 400+ verifiserte kundeanmeldelser<\/a>\n<\/div>\n

\ud83d\udce6 Hver ordre er dekket av v\u00e5r Reshipment Assurance Policy<\/strong><\/a> \u2014 hvis pakken din ikke ankommer innen 20 virkedager, sender vi ny.<\/p>\n

Hvorfor bestille fra MedsBase<\/h3>\n

V\u00e5re generiske legemidler kommer fra WHO-GMP-sertifiserte produsenter og sendes over hele verden i diskret, n\u00f8ytral emballasje \u2014 ingen legemiddelnavn p\u00e5 utsiden av pakken. Kortbetalinger h\u00e5ndteres av en regulert betalingsbehandler (kontoutskrifter viser en regulert kortbetalingsprosessor \u2014 aldri \u201cMedsBase\u201d eller noe legemiddelnavn). Krypto og SEPA bankoverf\u00f8rsel godtas ogs\u00e5. Hver ordre er dekket av v\u00e5r Reshipment Assurance Policy.<\/p>\n

What Is Rioci 1?<\/h2>\n

Rioci 1 is 1 mg riociguat tablets from a WHO-GMP certified manufacturer, supplied in 10-180 tablets. Riociguat was introduced by Bayer in 2013 as Adempas<\/strong> — the first sGC stimulator approved for human use. FDA-approved for two specific forms of pulmonary hypertension: pulmonary arterial hypertension (PAH, WHO Group 1) and chronic thromboembolic pulmonary hypertension (CTEPH, WHO Group 4) — the only oral drug approved for inoperable CTEPH.<\/p>\n

Pulmonal arteriell hypertensjon (PAH) er ikke systemisk hypertensjon.<\/strong> PAH refererer spesifikt til \u00f8kt trykk i den pulmonale arterielle sirkulasjonen (\u226520 mmHg gjennomsnittlig pulmonalt arterielt trykk med pulmonal vaskul\u00e6r motstand \u22652 Wood Units if\u00f8lge ESC\/ERS-retningslinjer fra 2022). Det er sjeldent (ansl\u00e5tt 15-50 per million voksne), progressivt, og uten behandling har det d\u00e5rlig prognose (historisk 5-\u00e5rs overlevelse \u223c30%). Moderne PAH-m\u00e5lrettet behandling har forbedret 5-\u00e5rs overlevelse til 60-70% i ekspertsentre.<\/p>\n

Candidates for Rioci 1 have been diagnosed at a PAH specialist centre via right heart catheterisation, with WHO\/NYHA functional class II-IV symptoms and confirmed PAH (WHO Group 1) or — for riociguat — inoperable or persistent CTEPH (WHO Group 4). This is not a drug for ordinary hypertension or for self-initiated therapy.<\/p>\n

How Riociguat Works<\/h2>\n

Directly activates soluble guanylate cyclase (the NO receptor) in pulmonary arterial smooth muscle, raising cGMP and producing pulmonary vasodilation. Unlike PDE5 inhibitors, riociguat stimulates sGC even in the absence of NO, giving activity in NO-deficient vascular beds characteristic of PAH and CTEPH.<\/p>\n

Bevis<\/h2>\n

PATENT-1 (2013)<\/strong> — riociguat in 443 PAH patients; 6-minute walk distance improved by 30 m vs placebo, with better WHO functional class and delayed clinical worsening. CHEST-1 (2013)<\/strong> — riociguat in 261 inoperable or persistent CTEPH patients; 6-minute walk improved by 46 m vs placebo.<\/p>\n

Dosering og Overv\u00e5king<\/h2>\n

Dosering:<\/strong> Start 1 mg three times daily (8-hour intervals); titrate every 2 weeks by 0.5 mg increments based on systolic BP (must remain >95 mmHg) and symptoms. Target dose 2.5 mg three times daily.<\/p>\n

Overv\u00e5kning:<\/strong> ved baseline og deretter hver 3.-6. m\u00e5ned \u2014 WHO funksjonsklasse, 6-minutters gangavstand, NT-proBNP, gjentatt ekkokardiografi, og (med lengre intervaller) h\u00f8yre hjertekateterisering. Alt utf\u00f8rt gjennom et spesialisert PAH-senter.<\/p>\n

BP monitoring:<\/strong> systolic BP must remain >95 mmHg; uptitration paused or reversed on symptomatic hypotension.<\/p>\n

Bivirkninger<\/h2>\n